The polymerase chain reaction (pcr) technologies market has seen considerable growth due to a variety of factors.
• The polymerase chain reaction (PCR) technologies market has seen substantial growth in recent years. It will increase from $14.58 billion in 2024 to $16.36 billion in 2025, with a compound annual growth rate (CAGR) of 12.2%.
This growth is attributed to the rise in genome-based drug development, the increasing prevalence of genetic disorders and target diseases, the growing use of miniaturized portable devices, biomarker profiling, and the rising demand for personalized medicine.
The polymerase chain reaction (pcr) technologies market is expected to maintain its strong growth trajectory in upcoming years.
• The polymerase chain reaction (PCR) technologies market is set to grow significantly, reaching $25.76 billion by 2029 with a CAGR of 12.0%.
This growth is fueled by rising demand for rapid and accurate disease diagnosis, forensics, real-time PCR, and diagnostic testing. Major trends include NGS integration, RNA analysis, single-cell PCR, AI, and point-of-care testing.
The growth of the PCR technologies market is anticipated to be driven by the escalating occurrence of infectious diseases. These diseases, caused by pathogenic microorganisms like bacteria, viruses, fungi, or parasites, can be directly or indirectly transmitted from one person to another. The concerningly rising prevalence of such diseases points to the mounting challenges presented by pathogens, possibly due to aspects like globalization, urbanization, antimicrobial resistance, and alterations in the environment. PCR technologies, by identifying and amplifying the specific genetic substance of pathogens, play a crucial role in reducing the occurrence of infectious diseases with their high sensitivity and accuracy for identification and diagnosis. For example, in November 2023, the World Health Organization (WHO) in Switzerland, a specialized United Nations agency focusing on international public health, predicts a global occurrence of 10.6 million tuberculosis (TB) cases in 2022, impacting 5.8 million men, 3.5 million women, and 1.3 million children. Consequently, the growing occurrence of infectious diseases is fuelling the progress of the PCR technologies market.
The polymerase chain reaction (PCR) technologies market covered in this report is segmented –
1) By Product: Reagents And Consumables, Instruments, Software, Services
2) By Technology: Real-Time Polymerase Chain Reaction, Conventional Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Multiplex Real-Time (RT) Polymerase Chain Reaction, Hot Start Polymerase Chain Reaction, Other Technologies
3) By Application: Gene Expression Analysis, Genetic Sequencing, Genotyping, Nucleic Acid Synthesis, Standard Validation, Point Of Care Diagnostics, Environmental Application, Other Applications
4) By End Users: Hospitals And Diagnostic Centers, Research Laboratories And Academic Institutes, Pharmaceutical And Biotechnology Companies, Other End Users
Subsegments:
1) By Reagents And Consumables: Pcr Master Mixes, Primers And Probes, Dna Or Rna Extraction Kits, Pcr Enzymes, Buffers And Solutions, Pcr Plates, Tubes, And Strips, Nucleotides
2) By Instruments: Pcr Machines (Thermal Cyclers), Real-Time Pcr Systems (Qpcr Systems), Digital Pcr Systems, Automated Pcr Platforms, Gel Electrophoresis Systems, Pcr Workstations
3) By Software: Pcr Data Analysis Software, Real-Time Pcr Software, Digital Pcr Software, Sequence Analysis Software, Multiplex Pcr Software, Laboratory Information Management Systems (Lims) For Pcr
4) By Services: Pcr Testing Services, Custom Pcr Primer Design Services, Pcr Training And Consultation Services, Pcr Sample Analysis Services, Pcr-based Diagnostic Services, Technical Support And Maintenance Services For Pcr Equipment
Significant players within the PCR technologies market, such as F. Hoffmann-La Roche AG, are concentrating their efforts on innovation and the creation of next-gen quantitative polymerase chain reaction (qPCR) methodologies. These advancements aim to enhance the precision, sensitivity, and productivity within the field of molecular diagnostics. qPCR technology, which quantifies unique DNA sequences within samples and facilitates real-time tracking and amplification, has become crucial in both scientific and medical sectors. F. Hoffmann-La Roche AG, based in Switzerland, introduced the LightCycler PRO System in November 2023, a state-of-the-art qPCR system engineered to meet the evolving clinical needs associated with molecular diagnostics and address public health issues. This system represents the pinnacle of qPCR technology for clinical diagnostics and research. It not only improves performance and usability but also acts as a bridge linking translational research and in vitro diagnostics. The system uses gold-standard technology, guaranteeing the quality, accuracy, and dependability required for accurate patient diagnoses and informed clinical decision-making.
Major companies operating in the polymerase chain reaction (PCR) technologies market are:
• F. Hoffmann-La Roche Ltd.
• Bayer Corporation
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Danaher Corporation
• Siemens Healthineers AG
• Becton
• Dickinson and Company (BD)
• GE Healthcare Technologies LLC
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Eurofins Scientific SE
• Agilent Technologies Inc.
• Illumina Inc.
• PerkinElmer Inc.
• bioMérieux SA
• Beckman Coulter Inc.
• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Natera Inc.
• BGI Genomics Co. Ltd.
• Cepheid
• NeoGenomics Laboratories Inc.
• Ambry Genetics Corporation
• Veritas Genetics Inc.
North America was the largest region in the PCR technologies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymerase chain reaction (PCR) technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.